ATLCAR.CD30 Cells

Phase 2Biologic

UUNC Lineberger Comprehensive Cancer Center

ATLCAR.CD30 Cells is one of 86 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Germ Cell TumorCompleted

LymphomaPhase 2

Active, not recruiting

Germ Cell TumorPhase 2

Completed

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

ATLCAR.CD30 Cells

UUNC Lineberger Comprehensive Cancer Center

Phase 2

3 7

Tafasitamab

Incyte

Preclinical

7 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2037

Phase 1Active, not recruiting

Lymphoma

NCT02663297

Q3 2038

Phase 2Recruiting

Lymphoma

NCT04083495

Q4 2039

PreclinicalActive, not recruiting

Lymphoma

NCT02690545

Clinical

Trials by Indication[1]

Lymphoma3 trials

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04083495·20 enrolled

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT02663297·18 enrolled

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Preclinical·NCT02690545·38 enrolled

Germ Cell Tumor1 trial

Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05634785·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ATLCAR.CD30 Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATLCAR.CD30 Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATLCAR.CD30 Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUNC Lineberger Comprehensive Cancer Center

ATLCAR.CD30 Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2037

Q3 2038

Q4 2039

Trials by Indication[1]

Lymphoma3 trials

Germ Cell Tumor1 trial

References

Drug Info

Quick Facts

Related News